JPMorgan discusses with management Setrusumab considerations heading into ORBIT/COSMIC and provides updates on YE25 on a conference call to be held on July 14 at 11:30 am hosted by JPMorgan. Webcast Link
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RARE:
- Ultragenyx price target lowered to $79 from $80 at BofA
- Positive Outlook on Ultragenyx Pharmaceutical Despite Setback with UX111 Approval
- Ultragenyx announces Health Canada extended approval of Evkeeza
- Ultragenyx price target lowered to $55 from $65 at Morgan Stanley
- Ultragenyx falls 4% to $28.41 after FDA rejection letter for gene therapy